Company: NCEL
Filing Date: 2025-01-31
Form Type: 425
Source: 0001213900-25-008564
Chunk: 1

Company: NewcelX Ltd.
Filing Date: 2025-01-31
Form: 425
Chunk 1
---
 | /s/ Alexander 
 Zwyer         |                         |
|:-----------------------|:-----------------------|:--------------|:------------------------|
|                        |                        | Name:         | Alexander Zwyer         |
|                        |                        | Title:        | Chief Executive Officer |

<div align='center'>2</div>

Exhibit 99.1

<div align='center'>Kadimastem Shareholders Approved the Merger with NLS Pharmaceutics</div>

ZURICH, SWITZERLAND and NESS ZIONA, ISRAEL — January 31, 2025
/ NLS Pharmaceutics Ltd. (“NLS”) (Nasdaq: NLSP), a Swiss clinical-stage biopharmaceutical company focused on the discovery
and development of innovative therapies for rare and complex central nervous system disorders, and Kadimastem Ltd. (“Kadimastem”)
(TASE: KDST.TA), a clinical-stage cell therapy company developing and manufacturing “off-the-shelf” allogeneic cell products
for the treatment of neurodegenerative diseases and potential cure for diabetes, are pleased to announce that in a special general meeting
of shareholders held yesterday, Kadimastem’s shareholders approved the merger with NLS (the “Merger”). This key milestone
brings NLS and Kadimastem one step closer to creating a combined Nasdaq-traded biotechnology company with a robust portfolio of advanced
therapies for neurodegenerative diseases and diabetes.

NLS is also planning to convene a shareholder meeting for final approval
of the Merger. The collaborative effort between NLS and Kadimastem underscores the companies’ commitment to advance innovative solutions
that address unmet medical needs in the biopharmaceutical sector.

Ronen Twito, Executive Chairman and Chief Executive Officer of Kadimastem, stated, “We are happy that our shareholders have approved this significant Merger with NLS. We believe that this approval shows
the shareholders’ appreciation of the anticipated value creation from the Merger to leverage NLS’s and Kadimastem’s
combined strengths in biotechnology. We look forward to completing the Merger and unlocking new opportunities for growth and innovation.”

Alex Zwyer, Chief Executive Officer of NLS, commented,“Receiving
approval from Kadimastem’s shareholders is a significant step forward in the Merger process. We look forward to the potential benefits
of bringing our two companies together and